Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Jones, Jeffrey, Mato, Anthony, Coutre, Steven, Byrd, John C., Furman, Richard R., Hillmen, Peter, Osterborg, Anders, Tam, Constantine, Stilgenbauer, Stephan, Wierda, William G., Heerema, Nyla A., Eckert, Karl, Clow, Fong, Zhou, Cathy, Chu, Alvina D., James, Danelle F., O'Brien, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120509/
https://ncbi.nlm.nih.gov/pubmed/29873072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados